These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31452606)

  • 1. Potential Impact on Lipoprotein Subfractions in Type 2 Diabetes.
    Kamijo Y; Ishii H; Yamamoto T; Kobayashi K; Asano H; Miake S; Kanda E; Urata H; Yoshida M
    Clin Med Insights Endocrinol Diabetes; 2019; 12():1179551419866811. PubMed ID: 31452606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Canagliflozin on High-Density Lipoprotein Cholesterol and Angiopoietin-Like Protein 3 in Type 2 Diabetes Mellitus.
    Liu S; Ke J; Feng X; Wang Z; Wang X; Yang L; Zhao D
    J Diabetes Res; 2024; 2024():2431441. PubMed ID: 38577301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
    Zaccardi F; Webb DR; Htike ZZ; Youssef D; Khunti K; Davies MJ
    Diabetes Obes Metab; 2016 Aug; 18(8):783-94. PubMed ID: 27059700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes.
    Bode B; Stenlöf K; Harris S; Sullivan D; Fung A; Usiskin K; Meininger G
    Diabetes Obes Metab; 2015 Mar; 17(3):294-303. PubMed ID: 25495720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
    Inagaki N; Goda M; Yokota S; Maruyama N; Iijima H
    Adv Ther; 2015 Nov; 32(11):1085-103. PubMed ID: 26530268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
    Lee S
    Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum cholesterol and triglyceride reference ranges of twenty lipoprotein subclasses for healthy Japanese men and women.
    Furusyo N; Ai M; Okazaki M; Ikezaki H; Ihara T; Hayashi T; Hiramine S; Ura K; Kohzuma T; Schaefer EJ; Hayashi J
    Atherosclerosis; 2013 Dec; 231(2):238-45. PubMed ID: 24267234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical use of sodium-glucose co-transporter-2 inhibitors in Chinese patients with type 2 diabetes mellitus.
    Chan WB
    Singapore Med J; 2019 Jun; 60(6):309-313. PubMed ID: 30402655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol.
    Jojima T; Sakurai S; Wakamatsu S; Iijima T; Saito M; Tomaru T; Kogai T; Usui I; Aso Y
    Int J Cardiol; 2021 May; 331():243-248. PubMed ID: 33556413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Streptozotocin-Treated High Fat Fed Mice: A New Type 2 Diabetes Model Used to Study Canagliflozin-Induced Alterations in Lipids and Lipoproteins.
    Yu T; Sungelo MJ; Goldberg IJ; Wang H; Eckel RH
    Horm Metab Res; 2017 May; 49(5):400-406. PubMed ID: 28395380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: Meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type.
    Bechmann LE; Emanuelsson F; Nordestgaard BG; Benn M
    Atherosclerosis; 2024 Jul; 394():117236. PubMed ID: 37582673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of cholesterol levels of lipoprotein subclasses in human serum using anion-exchange high-performance liquid chromatography with a linear concentration gradient of sodium perchlorate.
    Ito R; Manita D; Yanai H; Hirowatari Y
    Ann Clin Biochem; 2023 Nov; 60(6):374-385. PubMed ID: 37194115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus.
    Shimabukuro M; Higa M; Tanaka H; Shimabukuro T; Yamakawa K; Masuzaki H
    Diabet Med; 2011 Jul; 28(7):856-64. PubMed ID: 21244474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of the efficacy and safety of canagliflozin in elderly patients with type 2 diabetes.
    Elmore LK; Baggett S; Kyle JA; Skelley JW
    Consult Pharm; 2014; 29(5):335-46. PubMed ID: 24849690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin.
    Hayashi T; Fukui T; Nakanishi N; Yamamoto S; Tomoyasu M; Osamura A; Ohara M; Yamamoto T; Ito Y; Hirano T
    Cardiovasc Diabetol; 2017 Jan; 16(1):8. PubMed ID: 28086872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
    Brady JA; Hallow KM
    J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study.
    Rau M; Thiele K; Korbinian Hartmann NU; Möllmann J; Wied S; Böhm M; Scharnagl H; März W; Marx N; Lehrke M
    Atherosclerosis; 2021 Aug; 330():8-13. PubMed ID: 34218214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of insulin analog initiation therapy on LDL/HDL subfraction profile and HDL associated enzymes in type 2 diabetic patients.
    Aslan I; Kucuksayan E; Aslan M
    Lipids Health Dis; 2013 Apr; 12():54. PubMed ID: 23617853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.
    Kones R
    Vasc Health Risk Manag; 2013; 9():617-70. PubMed ID: 24174878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.